HC Wainwright Increases Alto Neuroscience (NYSE:ANRO) Price Target to $55.00

Alto Neuroscience (NYSE:ANRO) had its target price boosted by research analysts at HC Wainwright from $50.00 to $55.00 in a report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 63.54% from the stock’s previous close.

A number of other equities research analysts also recently commented on the stock. Wall Street Zen raised shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research report on Saturday. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Wedbush boosted their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Thursday. Bank of America started coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Wolfe Research initiated coverage on Alto Neuroscience in a research note on Friday, May 22nd. They issued an “outperform” rating on the stock. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Alto Neuroscience has a consensus rating of “Moderate Buy” and a consensus target price of $37.25.

Alto Neuroscience Stock Up 4.6%

Shares of ANRO traded up $1.49 during midday trading on Monday, hitting $33.63. The company had a trading volume of 250,108 shares, compared to its average volume of 371,723. Alto Neuroscience has a 1 year low of $3.05 and a 1 year high of $33.99. The firm has a market capitalization of $1.18 billion, a P/E ratio of -13.87 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The company’s 50-day simple moving average is $25.97 and its 200-day simple moving average is $22.79.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08. As a group, sell-side analysts expect that Alto Neuroscience will post -3 EPS for the current year.

Institutional Trading of Alto Neuroscience

Several institutional investors have recently modified their holdings of the stock. Commodore Capital LP purchased a new stake in shares of Alto Neuroscience in the 4th quarter valued at about $32,453,000. Perceptive Advisors LLC grew its stake in Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after buying an additional 1,629,027 shares during the last quarter. Vestal Point Capital LP increased its position in Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after buying an additional 1,535,000 shares during the period. Spruce Street Capital LP increased its position in Alto Neuroscience by 494.7% during the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock worth $29,116,000 after buying an additional 1,102,366 shares during the period. Finally, Vivo Capital LLC purchased a new stake in Alto Neuroscience in the fourth quarter valued at approximately $18,433,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.